论文部分内容阅读
为探讨静脉注射丙种球蛋白 (IVIG)对新生儿 ABO溶血病的疗效 ,随机将 42例 ABO溶血病新生儿分为 IVIG治疗组和常规治疗组 ,两组均于治疗前和治疗后分别查血红蛋白 ,网织红细胞、血清胆红素及 Ig G.A.M。结果 :IVIG组在皮肤黄疸消退 ,降低血清胆红素疗效方面均明显优于常规组 (P<0 .0 1 ) ,Ig G水平明显提高 (P<0 .0 1 ) Ig A与 Igm水平无变化 (P>0 .0 5 ) ;常规组在治疗 3～ 4天后血红蛋白水平显著低于治疗前 (P<0 .0 1 ) ,而 IVIG组血红蛋白水平与治疗前无显著性差异 (P>0 .0 5 ) ,IVIG投药量为 40 0 mg/kg.d、6 0 0 mg/kg.d、80 0 mg/kg.d,三种剂量均显示有效 ,以 80 0 mg/kg.d组退黄效果明显 ,但比较无统计学意义 (P>0 .0 5 )。结论 :IVIG对新生儿 ABO溶血病有确切疗效 ,有较高的临床使用价值
To investigate the efficacy of intravenous gamma globulin (IVIG) on neonatal ABO hemolytic disease, 42 newborns with ABO hemolytic disease were randomly divided into IVIG treatment group and conventional treatment group. Both groups before and after treatment were hemoglobin , Reticulocytes, serum bilirubin and Ig GAM. Results: The IVIG group was significantly better than the conventional group (P <0.01) in the regression of skin jaundice and the decrease of the serum bilirubin level, and the level of Ig G was significantly increased (P <0.01). The levels of Ig A and Igm (P> 0.05). The hemoglobin level of the conventional group was significantly lower than that before treatment (P <0. 01) after 3 to 4 days of treatment, while the level of hemoglobin in the IVIG group was not significantly different from that before treatment .0 5), IVIG dosage was 40 0 mg / kg.d, 600 mg / kg.d, 80 0 mg / kg.d, all three doses were effective, with 80 0 mg / kg.d group Jaundice effect was obvious, but there was no statistical significance (P> 0.05). Conclusion: IVIG has definite effect on neonatal ABO hemolytic disease and has high clinical value